peficitinib (Vonjo) Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Peficitinib is a pharmaceutical drug used for the treatment of rheumatoid arthritis. It belongs to the class of drugs known as Janus kinase inhibitors.   Wikipedia

Chemistry

  • SMILES: NC(=O)c1cnc2[nH]ccc2c1N[C@@H]3[C@@H]4CC5C[C@H]3C[C@@](O)(C5)C4
  • InChIKey: DREIJXJRTLTGJC-ZLBJMMTISA-N
  • Mol. Mass: 326.4
  • ALogP: 2.01
  • ChEMBL Molecule:
    peficitinib  
More Chemistry

Pharmacology

Alternative names

4-((5-hydroxy-2-adamantyl)amino)-1h-pyrrolo(2,3-b)pyridine-5-carboxamide | asp015k | asp-015k | jnj-54781532 | peficitinib

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Arthritis, Rheumatoid (Phase 3)

Colitis, Ulcerative (Phase 2)

Drug Interactions (Phase 1)

Healthy Volunteers (Phase 1)

Kidney Diseases (Phase 1)

Liver Diseases (Phase 1)

Pharmacokinetics (Phase 1)

Pharmacology (Phase 1)

Psoriasis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 34
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue